Navigation Links
Dendreon Reports Third Quarter 2008 Financial Results
Date:11/7/2008

onferences that

will be webcast. Both conferences will occur later this month and

include:

o Rodman & Renshaw 10th Annual Healthcare Conference

o Lazard Capital Markets 5th Annual Healthcare Conference

"The interim analysis of our Phase 3 IMPACT trial was an important milestone for us. We were encouraged to see a 20 percent reduction in the risk of death in the PROVENGE arm versus placebo at the time of this analysis in a patient population that currently has few appealing treatment options available," stated Mitchell H. Gold, M.D., president and chief executive officer of Dendreon Corporation. "Importantly, the results from this interim analysis are consistent with those from our previous Phase 3 studies at a similar follow-up time, and we are looking forward to the final analysis of the IMPACT trial in the middle of next year."

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets Trp-p8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com.

Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties surrounding the efficacy of PROVENGE to treat men suffering from prostate cancer, risks a
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
2. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
3. Dendreon Announces Webcast Presentation at UBS Global Life Sciences Conference
4. Dendreon Announces Webcast Presentation at Newsmakers in the Biotech Industry Conference
5. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
6. Dendreon Reports First Quarter 2008 Financial Results
7. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
8. Dendreon Announces Closing of Registered Direct Offering
9. Dendreon Announces $47 Million Registered Direct Offering
10. Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
11. FDA Agrees to Amend Dendreons Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014  Galmed Pharmaceuticals Ltd. (Nasdaq: ... focused on the development and commercialization of a once-daily, ... cholesterol gallstones, today announced financial results for the period ... Financial Summary: , Reported cash and cash equivalents ... $137,000 at December 31, 2013.  , Reported a ...
(Date:7/24/2014)... Tenn., July 24, 2014 -- A novel combination of ... Department of Energy,s Oak Ridge National Laboratory an unprecedented ... its unusual physical and electrochemical properties. , The ... oxygen affects the surface of a perovskite manganite, a ... The new avenue to understand surface behavior could benefit ...
(Date:7/24/2014)... worldwide rely on sophisticated equipment, trained personnel, and ... areas against terrorist attacks. A revolutionary new electronic ... make their job much easier. , The groundbreaking ... Tel Aviv University ,s School of Chemistry and ... the Herzliya company Tracense, picks up the scent ...
(Date:7/24/2014)... , July 24, 2014 Research ... "Global Cell Culture Market 2014-2018" report to ... Cell culture is the in vitro growth ... as research, cell studies, and biopharmaceutical production. Cell culture ... production. Cell culture instruments and cell culture consumables are ...
Breaking Biology Technology:Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6ORNL study reveals new characteristics of complex oxide surfaces 2Nano-sized chip 'sniffs out' explosives far better than trained dogs 2Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 2
... DIEGO, March 26 David Koos, Chairman and CEO ... Board: BMSN) announced today that the important discovery reported ... Institutes of Health (NIH; www.nih.gov ), which has ... validates a new direction for stem cell "storage" facilities ...
... (Nasdaq: NVAX ) today announced that it will ... release to be issued after 2:00 p.m. Eastern Time on ... call to discuss its financial results at 4:00 p.m. Eastern ... by Novavax President and Chief Executive Officer Dr. Rahul Singhvi ...
... - Extends Successful Existing Distribution Agreement for the ... Researchers Can Easily Access ZyGEM,s Growing Line of ... DNA Extraction and Is Ideally Suited to Automation ... HAMILTON, New Zealand, March 26 ZyGEM Corp. ...
Cached Biology Technology:NIH News Confirms Trend in Stem Cell 'Storage' Facilities, says CEO of San Diego-based Bio-Matrix Scientific Group 2Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call 2Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call 3ZyGEM Corp. and VWR International Europe BVBA Sign Agreement to Distribute Breakthrough DNA Extraction Technology in Europe 2ZyGEM Corp. and VWR International Europe BVBA Sign Agreement to Distribute Breakthrough DNA Extraction Technology in Europe 3ZyGEM Corp. and VWR International Europe BVBA Sign Agreement to Distribute Breakthrough DNA Extraction Technology in Europe 4
(Date:7/25/2014)... a molecular testing panel developed at UPMC greatly ... surgery for patients with thyroid nodules and cancer, ... Institute (UPCI), partner with UPMC CancerCenter., The test, ... other diagnostic testing agencies, improved the chances of ... percent, according to the study published this month ...
(Date:7/25/2014)... , July 25, 2014 ... consumers are turning to digital technology for online & ... NXTD), Google Inc. (NASDAQ: GOOG ), LifeLock ... V ), Apple Inc. (NASDAQ: ... NXT-ID, Inc., (OTCQB: NXTD) a biometric authentication company focused ...
(Date:7/24/2014)... sobering examples of how wildlife loss leads to conflict ... by Wildlife Conservation Society (WCS) Health & Ecosystems: ... calls for an interdisciplinary approach to tackle global biodiversity ... about 15% of the world,s people and provides protein ... It should come as no surprise that today,s unprecedented ...
Breaking Biology News(10 mins):Test increases odds of correct surgery for thyroid cancer patients 2Test increases odds of correct surgery for thyroid cancer patients 3Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 2Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 3Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 4Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 5Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 6New study draws links between wildlife loss and social conflicts 2
... mentally, but genetically everyone is very similar. That,s ... But with population research becoming more and more ... concerned that genetic research could awaken racist attitudes. ... geneticist James Watson claimed there are genes responsible ...
... new study by researchers at UC Davis Medical Center ... patients may be a result of their brains not ... drops in blood oxygen levels are more common than ... senior author Masud Seyal, a professor of neurology at ...
... 17, 2008) -- A "chip" or array that can quickly ... with chromosomal abnormalities proved an effective tool in prenatal diagnosis ... Medicine, said researchers in a report that appears in the ... In the report, a team led by Dr. Arthur Beaudet ...
Cached Biology News:Could genetic research awaken racist attitudes? 2Drops in blood oxygen levels may be key to sudden death in some epilepsy patients 2Drops in blood oxygen levels may be key to sudden death in some epilepsy patients 3Microarray analysis improves prenatal diagnosis 2Microarray analysis improves prenatal diagnosis 3
... the only Gradient thermal cycler which enables you ... a screen. ,Wide linear gradient - The ... an amazing range of,30C. Protocols can be optimised ... The Touchgene Gradient incorporates a large, 115 x ...
... bath, with a comprehensive array of accessories. ... baths with seamless, splash-water protected keypad offer ... (LED) indicating up to 6 temperature values ... MICROPROCESSOR technology with PID temperature control eliminates ...
... Stabilizer is an aqueous solution that contains ... stabilizing chemicals in a MOPS buffer (3-(N-Morpholino) ... This product contains a combination of 0.02% ... 300 (Rohm and Haas Company) as a ...
Request Info...
Biology Products: